Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar OklaBoston (67.51) Submitted: 11/14/2012 7:25:39 PM : Outperform Start Price: $0.75 PPHM Score: +21.79

No insider sales in 2 years, 13.35% insider ownership, and the fact that it's gotten of the 1 star list make this worth consideration, IMO. Charts look like a bottom formation as well.

Featured Broker Partners


Advertisement